BioCryst Pharmaceuticals (BCRX) Projected to Post Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $126.83 million for the quarter.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the prior year, the business earned $0.28 earnings per share. The business’s revenue was up 40.8% compared to the same quarter last year. On average, analysts expect BioCryst Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $8.93 on Friday. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -14.64 and a beta of 1.08. The firm has a 50 day simple moving average of $7.69 and a 200-day simple moving average of $7.80. BioCryst Pharmaceuticals has a 1-year low of $4.42 and a 1-year high of $9.50.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BCRX. Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.13.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.